Yi‐Ming Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi‐Ming Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Fang Xie
Department of Ultrasound The First Medical Center of PLA General Hospital Beijing China
1 shared publication - Jing Xiao
Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China
1 shared publication - Lin Yan
Department of Ultrasound, First Medical Center, Chinese PLA General Hospital
1 shared publication - Mingbo Zhang
Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China
1 shared publication - Xiao‐Qi Tian
Department of Ultrasound The First Medical Center of PLA General Hospital Beijing China
1 shared publication Ya‐Qiong Zhu
Department of Ultrasound The First Medical Center of PLA General Hospital Beijing China
1 shared publication
Latest Publications
- 1 March 2022
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (11) , 2789-2802
Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation
Objective High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastasis and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAF(V600E) mutation to screen high-risk PTC at early stage. Methods The targeted lipid nanobubbles carrying BRAF(V600E) antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAF(V600E) were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAF(V600E) were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging. Results The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAF(V600E) monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAF(V600E) overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAF(V600E) overexpression as compared to the untargeted lipid nanobubbles. Conclusion The targeted lipid nanobubbles carrying BRAF(V600E) antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.
- 1 March 2022
- Published by Wiley in Journal of Ultrasound in Medicine
- Vol. 41 (11) , 2789-2802
Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation
Objective High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastasis and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAF(V600E) mutation to screen high-risk PTC at early stage. Methods The targeted lipid nanobubbles carrying BRAF(V600E) antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAF(V600E) were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAF(V600E) were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging. Results The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAF(V600E) monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAF(V600E) overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAF(V600E) overexpression as compared to the untargeted lipid nanobubbles. Conclusion The targeted lipid nanobubbles carrying BRAF(V600E) antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.